Yuanyuan Xiao

Yuanyuan Xiao

Auto-generated profile, based on publicly available information

Yuanyuan Xiao

Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Center for Diabetes, Shanghai Key Clinical Center for Metabolic Disease, 600 Yishan Road, Shanghai 200233, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2023 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
YFYunyun Fang
Yunyun Fang
JZJingjing Zhang
Jingjing Zhang
LJLinlin Ji
Linlin Ji
CZChaoyu Zhu
Chaoyu Zhu
YXYuanyuan Xiao
Yuanyuan Xiao
LWLi Wei
Li Wei
Objective. To investigate the relationship between glucagon-like peptide-1 receptor gene polymorphisms and susceptibility to early onset type 2 diabetes. Methods. Samples from 316 type 2 diabetes patients with early onset type 2 diabetes (n=137) and late-onset type 2 diabetes (n=179) and 145 nondiabetic individuals were analyzed. Multiplex PCR combined with resequencing Hi-Reseq technology was used to detect single nucleotide polymorphisms of the glucagon-like peptide-1 receptor gene, and the allele frequency, genotype distribution, and clinical parameters were analyzed between each diabetes subgroup and the control group. Results. Sixteen single nucleotide polymorphisms were identified in the exonic region of the glucagon-like peptide-1 receptor gene according to the minor allele frequency (MAF>0.05) in the participants. Among these, the glucagon-like peptide-1 receptor rs3765467 (GA) mutation was statistically associated with early onset type 2 diabetes. Compared with that of the GG carriers, carriers of genotype AA at rs3765467 had a decreased risk of early onset type 2 diabetes after adjusting for sex and body mass index. In the dominant model, the frequencies of the rs3765467 AA+GA genotype were significantly decreased in the early onset type 2 diabetes group, and carriers of genotype AA+GA at rs3765467 had a decreased risk of early onset type 2 diabetes after adjusting for sex and body mass index. Moreover, fasting C peptide levels were significantly higher in GA+AA genotype carriers than those in GG genotype carriers. Conclusion. The glucagon-like peptide 1 receptor rs3765467 polymorphism was significantly associated with age at type 2 diabetes diagnosis and thus may be used as a marker to screen and detect individuals at risk of developing early onset type 2 diabetes.

20 April 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
YXYuanyuan Xiao
Yuanyuan Xiao
XLXiaoxia Liu
Xiaoxia Liu
LWLi Wei
Li Wei
WSWanwan Sun
Wanwan Sun
SPSee Pdf
See Pdf
Background and Aim(s): Metabolic dysfunction-associated steatotic liver disease (MASLD) lacks reliable early biomarkers. This study aimed to investigate the prognostic value of serum scEMC10 and establish a predictive model for MASLD.Methods: A 4.6-year prospective cohort study of 769 initially MASLD-free Chinese adults were conducted. Serum scEMC10 levels were measured via ELISA. Multivariable logistic regression identified independent predictors to develop the MASLD-scEMC10 model, which was compared against established indices using ROC-AUC analysis.Results: Baseline scEMC10 levels were significantly higher in participants who developed MASLD (4.60 vs. 2.55 ng/mL, P<0.001). scEMC10 was an independent predictor (OR=1.05, P<0.001). The MASLD-scEMC10 model (BMI, HbA1c, adiponectin, scEMC10) demonstrated superior predictive accuracy (AUC=0.8142, 95% CI: 0.758–0.870) compared to scEMC10 alone (AUC=0.6531, P<0.01) and other established indices like FLI, HIS, and ZJU.Conclusions: Serum scEMC10 is a significant independent predictor of MASLD. The proposed MASLD-scEMC10 model provides excellent predictive accuracy, suggesting an etiological role for scEMC10 in MASLD and offering a valuable tool for early clinical risk stratification.